Biomedical research in the 21st century will depend increasingly on insights gained from network interaction studies: understanding the complex, multifunctional relationships between molecules, structures and processes within a cell that give rise to all of its normal and diseased behaviors. The Cancer Cell Map Initiative is harnessing this new approach to catalyze a major phase transition in cancer research, toward network-based precision medicine.
read more about CCMI’s mission »
Read a discussion of recent progress that enables creation of cancer cell maps across a range of tumor types and how they can be used to target networks disrupted in individual patients, significantly accelerating the development of precision medicine.
Citation: The cancer cell map initiative: defining the hallmark networks of cancer. Krogan NJ, Lippman S, Agard DA, Ashworth A, Ideker T. Mol Cell. 2015 May 21;58(4):690-8. PMID: 26000852
Providing a rationale for EGFR and NF-κB co-inhibition to eliminate residual disease and enhance patient responses.
Citation: NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Blakely et al. Cell Rep. 2015 Apr 7;11(1):98-110. PMID: 25843712
Using engineered cells and systems interaction maps, we charted the influence of 51 aberrant cancer genes on 90 drug responses.
Citation: Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Martins et al. Cancer Discov. 2015 Feb;5(2):154-67. PMCID: PMC4407699
Here we introduce network-based stratification (NBS), a method to integrate somatic tumor genomes with gene networks. This approach allows for stratification of cancer into informative subtypes by clustering together patients with mutations in similar network regions.
Citation: Network-based stratification of tumor mutations. Hofree M, Shen JP, Carter H, Gross A, Ideker T. 2013 Nov; 10(11):1108-15. PMCID: PMC3866081
Comprehensive analysis of the molecular and clinical features of Head and neck squamous cell carcinoma (HNSCC)
Citation: Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.. Gross AM, et al. Nat Genet. 2014 Sept; 46(9):939-43. PMID: 25086664